普萘洛尔治疗肝炎性肝硬化腹腔积液患者的疗效观察  

Efficacy Observation of Propranolol in the Treatment of Liver Cirrhosis Patients with Ascites Caused by Hepatitis

作　　者：李鹏飞 

机构地区：[1]湖南省涟源市人民医院,湖南娄底417100

出　　处：《临床医学工程》2015年第10期1321-1322,共2页Clinical Medicine & Engineering

摘　　要：目的探讨普萘洛尔治疗肝炎性肝硬化腹腔积液患者的临床效果。方法选择2013年6月至2014年12月在本院就诊的肝炎性肝硬化腹腔积液患者120例,随机分为观察组和对照组各60例。对照组给予单纯螺内酯治疗,观察组在对照组的基础上给予普萘洛尔治疗。比较两组的治疗有效率和门静脉内径改善情况。结果观察组患者治疗总有效率为90.0%,显著高于对照组患者的70.0%,差异具有统计学意义(P<0.05)。两组患者治疗前门静脉内径相比差异不显著(P>0.05),两组患者治疗后门静脉内径均显著改善,且观察组患者改善程度明显优于对照组,差异均具有统计学意义(P<0.05)。结论对肝炎性肝硬化腹腔积液患者使用普萘洛尔进行治疗,能够显著改善患者的门静脉内径并提高治疗的有效率,值得临床推广和应用。Objective To study the clinical effect of propranolol in the treatment of liver cirrhosis patients with ascites caused by hepatitis. Methods 120 cases of liver cirrhosis patients with ascites caused by hepatitis admitted to our hospital from June 2013 to December 2014 were selected and randomly divided into observation group and control group, with 60 cases in each group. Patients in control group were given simple spironolactone for treating, patients in observation group were given propranolol on the basis of control group for treating. The effective rate and improvement of portal vein diameter were analyzed and compared between two groups. Results The effective rate of observation group was 90.0%, significantly higher than 70.0%of control group, with statistical difference （P〈0.05）. The portal vein diameter of two groups before the treatment had no statistical difference （P〉0.05）, and after the treatment, the portal vein diameter of two groups were significantly improved, and the improvement degree of observation group was significantly better than that of control group, all the difference was statistical （P〈0.05）. Conclusions For liver cirrhosis patients with ascites caused by hepatitis, propranolol can significantly improve the portal vein diameter and increase the treatment effective rate, which is worthy of promotion and application.

关 键 词：普萘洛尔 肝炎 肝硬化 腹腔积液 

分 类 号：R575.2[医药卫生—消化系统]